Filtered By:
Specialty: Drugs & Pharmacology
Infectious Disease: COVID-19
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 161 results found since Jan 2013.
Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports
CONCLUSIONS: Our study demonstrates that remdesivir, a novel drug applied to the treatment of COVID-19, does not have a significant association with adverse neurologic or psychiatric reactions in the real-world setting.PMID:34919240 | DOI:10.26355/eurrev_202112_27435
Source: European Review for Medical and Pharmacological Sciences - December 17, 2021 Category: Drugs & Pharmacology Authors: S Lee J W Yang S Y Jung M S Kim D K Yon S W Lee H-C Kang E Dragioti K Tizaoui L Jacob A Koyanagi J-E Salem K Kostev A Lascu J I Shin J H Kim L Smith Source Type: research
Mini-Review on SARS-CoV-2 Infection and Neurological Manifestations: A Perspective
CNS Neurol Disord Drug Targets. 2021 Jul 6. doi: 10.2174/1871527320666210706103422. Online ahead of print.ABSTRACTThe coronavirus, also known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus-19), with its rapid rate of transmission, has progressed with a great impact on respiratory function and mortality worldwide. The nasal cavity is the promising gateway of SARS-CoV-2 to reach the brain via systemic circulatory distribution. Recent reports have revealed that the loss of involuntary process of breathing control into the brainstem that results in death is a signal of neurological involvement. Early neurologica...
Source: CNS and Neurological Disorders Drug Targets - December 30, 2021 Category: Drugs & Pharmacology Authors: Vishal Chavda Arif Tasleem Jan Dhananjay Yadav Source Type: research
Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports
CONCLUSIONS: Our study demonstrates that remdesivir, a novel drug applied to the treatment of COVID-19, does not have a significant association with adverse neurologic or psychiatric reactions in the real-world setting.PMID:34919240 | DOI:10.26355/eurrev_202112_27435
Source: European Review for Medical and Pharmacological Sciences - December 17, 2021 Category: Drugs & Pharmacology Authors: S Lee J W Yang S Y Jung M S Kim D K Yon S W Lee H-C Kang E Dragioti K Tizaoui L Jacob A Koyanagi J-E Salem K Kostev A Lascu J I Shin J H Kim L Smith Source Type: research
Mini-Review on SARS-CoV-2 Infection and Neurological Manifestations: A Perspective
CNS Neurol Disord Drug Targets. 2021 Jul 6. doi: 10.2174/1871527320666210706103422. Online ahead of print.ABSTRACTThe coronavirus, also known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus-19), with its rapid rate of transmission, has progressed with a great impact on respiratory function and mortality worldwide. The nasal cavity is the promising gateway of SARS-CoV-2 to reach the brain via systemic circulatory distribution. Recent reports have revealed that the loss of involuntary process of breathing control into the brainstem that results in death is a signal of neurological involvement. Early neurologica...
Source: CNS and Neurological Disorders Drug Targets - December 30, 2021 Category: Drugs & Pharmacology Authors: Vishal Chavda Arif Tasleem Jan Dhananjay Yadav Source Type: research
Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports
CONCLUSIONS: Our study demonstrates that remdesivir, a novel drug applied to the treatment of COVID-19, does not have a significant association with adverse neurologic or psychiatric reactions in the real-world setting.PMID:34919240 | DOI:10.26355/eurrev_202112_27435
Source: European Review for Medical and Pharmacological Sciences - December 17, 2021 Category: Drugs & Pharmacology Authors: S Lee J W Yang S Y Jung M S Kim D K Yon S W Lee H-C Kang E Dragioti K Tizaoui L Jacob A Koyanagi J-E Salem K Kostev A Lascu J I Shin J H Kim L Smith Source Type: research
Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence
CONCLUSION AND RELEVANCE: When compared with UFH, enoxaparin was associated with a significant reduction in thrombotic events or mortality among COVID-19 patients. The results need confirmation from randomized controlled trials.PMID:35942505 | DOI:10.1177/10600280221115299
Source: The Annals of Pharmacotherapy - August 9, 2022 Category: Drugs & Pharmacology Authors: Lina H AlLehaibi Mukhtar Alomar Abdulaziz Almulhim Sarah Al-Makki Nazar R Alrwaili Shahad Al-Bassam Semat Alsultan Jenan Al Saeed Mohammad Alsheef Ivo Abraham Ahmad Alamer Source Type: research
